Tarsus Pharmaceuticals
TARS
41 hedge funds and large institutions have $410M invested in Tarsus Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 40 → 41 (+1)
0.01% more ownership
Funds ownership: 62.79% → 62.8% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
22% less capital invested
Capital invested by funds: $523M → $410M (-$113M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.07M |
| 2 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$780K |
| 3 |
BlackRock
New York
|
+$642K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$523K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$455K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.2M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$827K |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$470K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$317K |
| 5 |
Morgan Stanley
New York
|
-$263K |
TARS Hedge Fund Activity: Q1 2021 in Review
41 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q1 2021, worth a combined $410M — down 22% from $523M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TARS positions and 5 closed out — a net gain of 1 holder — while 11 added to existing stakes and 12 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.07M. The largest seller was Millennium Management, cutting an estimated $2.2M.
- 41 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q1 2021, up from 40 in Q4 2020.
- Funds reported $410M of Tarsus Pharmaceuticals stock for Q1 2021, down 22% quarter-over-quarter.
- 6 funds opened new Tarsus Pharmaceuticals positions in Q1 2021 and 5 closed out, a net change of +1 holder.
- The largest Tarsus Pharmaceuticals buyer in Q1 2021 was Goldman Sachs, an estimated $1.07M added.
- The largest Tarsus Pharmaceuticals seller in Q1 2021 was Millennium Management, an estimated $2.2M sold.
Based on aggregated 13F filings for Q1 2021.